Synopsis:It is a new type of antiplatelet agglutination drug successfully developed by AstraZeneca. It is the first reversible binding oral P2Y12 adenosine diphosphate receptor antagonist in the world. It can reversibly act on purinoceptor2 (P2) subtype p2y1chemicalbook2 on vascular smooth muscle cells (VSMC) without metabolic activation, It has obvious inhibitory effect on platelet aggregation caused by adenosine diphosphate (ADP), and takes effect rapidly after oral use, which can effectively improve the symptoms of patients with acute coronary heart disease. Unlike thiophenopyridine drugs, ticagrel is a reversible inhibitor of P2Y12 receptor, so it is particularly suitable for patients who need to undergo anticoagulant treatment before surgery.
Structural formula:
Properties
Summary
API for reducing cardiovascular death and heart attack in patients with acute coronary syndrome (ACS).
Manufacturing
